Lexicon Pharmaceuticals (LXRX) Capital Expenditures Growth (1y) (2011 - 2024)
Lexicon Pharmaceuticals (LXRX) Capital Expenditures Growth (1y) (2011 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 888.49 Mn | 717.83 Mn | 20.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 269.88% |
| Jun 30, 2024 | 79.86% |
| Sep 30, 2023 | 1,975.00% |
| Mar 31, 2023 | 226.32% |
| Dec 31, 2022 | 5,317.39% |
| Sep 30, 2022 | -98.12% |
| Mar 31, 2022 | 100.00% |
| Dec 31, 2021 | -57.41% |
| Sep 30, 2021 | 545.45% |
| Mar 31, 2019 | 75.00% |
| Dec 31, 2018 | 825.00% |
| Sep 30, 2018 | -95.08% |
| Jun 30, 2018 | -78.87% |
| Mar 31, 2018 | -56.52% |
| Dec 31, 2017 | -97.30% |
| Sep 30, 2017 | 281.25% |
| Jun 30, 2017 | 446.15% |
| Mar 31, 2017 | 70.37% |
| Dec 31, 2016 | -39.84% |
| Sep 30, 2016 | -91.30% |